Journals / Türk Toraks Dergisi / 2011 / Cilt: 12 - Sayı: 2

Wegener granulomatosis accompanying rheumatoid arthritis: A case report

Romatoid artrit ve Wegener granülomatozu birlikteliği: Bir olgu sunumu

Pages
72–75
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The effect of that coincidence on treatment decision was aimed at discussing a case report as being a rare condition.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease that can lead to systemic involvement especially related to significant joint pain and disability.
📊
Key Findings & Data:Tumour necrosis factor (TNF) has a pivotal role in its pathogenesis.
💡
Conclusion & Impact:The effect of that coincidence on treatment decision was aimed at discussing a case report as being a rare condition.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease that can lead to systemic involvement especially related to significant joint pain and disability. Tumour necrosis factor (TNF) has a pivotal role in its pathogenesis. TNF also has effects on the formation of granuloma and the defensive mechanisms against the intracellular injuries. While a case with RA has been evaluated before the TNF alpha antagonist treatment, the presence of respiratory symptoms and bilateral cavitary lung lesions led to further investigations and was diagnosed as accompanying Wegener granulomatosis. The effect of that coincidence on treatment decision was aimed at discussing a case report as being a rare condition.

Özet

Romatoid artrit (RA), belirgin eklem ağrısı ve kısıtlılığı ile seyreden, sistemik tutulumu olan kronik, progresif inflamatuvar bir hastalıktır. Patogenezinde, tümör nekrozis faktör (TNF) anahtar role sahiptir. TNF'nin granülom formasyonu ve intrasellüler patojenlere karşı vücut savunma sisteminde önemli bir rolü vardır. RA tedavisi için TNF alfa blokeri verilmesi öncesinde değerlendirilen 42 yaşında kadın olguda, sabahları olan kuru öksürük ve nefes darlığı gibi solunumsal yakınmalar mevcuttu. Fizik incelemesi normal olup bilateral kaviter akciğer lezyonları saptanması üzerine serolojik testler ve akciğer biyopsisi yapıldı. Sonuçta Wegener granülomatozu tanısı kondu. Seyrek rastlanan bu birlikteliği ve tedavi kararına etkisini tartışmayı amaçladık.

🔖

Cite This Article

ÖZTÜRK, E., KİLER, G., ÇOBANKARA, V., ŞENEL, S., YUNCU, G. (2011). Wegener granulomatosis accompanying rheumatoid arthritis: A case report. Türk Toraks Dergisi, Cilt: 12 - Sayı: 2, 72–75. https://ajindex.com/articles/329538

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Richard-Miceli C, Dougados M. Tumor necrosis factor-alpha blockers in rheumatoid arthritis: Review of clinical experience. BioDrugs, 2001; 15: 251-9
  2. Kasai S, Tokuda H, Otsuka Y. Two cases of respiratory infection complicating treatment with infliximab. Nihon Kokyuki Gakkai Zasshi, 2007; 45: 366-71
  3. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalance, annual mortality, and geographic disease distrubition from population-based data sources. Arthritis Rheum 1996; 39: 87-92
  4. Richard A. DeRemee. Pulmonary Vasculitis. In: Alfred P. Fishman, MD; ed. Pulmonary Disease and Disorders.3rd ed. McGraw-Hill NewYork, 1997; 1357-74
  5. Bilgen I, Demirpolat G, Savaş R, ve ark. Benign kistik ve kaviter akciğer lezyonları. Toraks Dergisi 2003; 4: 95-9
  6. Douglas G, Bird K, Flume P, Silver R, Bolster M. Wegener's granulomatosis in patients with rheumatoid arthritis. Journal of Rheumatology 2003; 30: 2064-9
  7. Van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9
  8. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007; 46: 327-34
  9. Ellerin T, Rubin RH, Weinbatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48: 3013-22
  10. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managemet. Lancet Infect Dis, 2003; 3: 148-55
  11. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Sys Rev, 2005; 20: CD005113
  12. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with İnfliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J 2001; 45: 1098-104
  13. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infections disease associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-5
  14. Türkiye'de Tüberkülozun Kontrolü için Başvuru Kitabı. T.C. Sağlık Bakanlığı Verem Savaşı Daire Başkanlığı. Ankara, 2003; 15-7
  15. Marcoux BS, De Bandt M. Vasculitides induced by TNF alpha antagonists: a study